0001193125-23-150484.txt : 20230522 0001193125-23-150484.hdr.sgml : 20230522 20230522161556 ACCESSION NUMBER: 0001193125-23-150484 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20230509 ITEM INFORMATION: Bankruptcy or Receivership ITEM INFORMATION: Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement ITEM INFORMATION: Cost Associated with Exit or Disposal Activities ITEM INFORMATION: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230522 DATE AS OF CHANGE: 20230522 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Athenex, Inc. CENTRAL INDEX KEY: 0001300699 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 431985966 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38112 FILM NUMBER: 23944626 BUSINESS ADDRESS: STREET 1: 1001 MAIN STREET STREET 2: SUITE 600 CITY: BUFFALO STATE: NY ZIP: 14203 BUSINESS PHONE: 716-898-8625 MAIL ADDRESS: STREET 1: 1001 MAIN STREET STREET 2: SUITE 600 CITY: BUFFALO STATE: NY ZIP: 14203 FORMER COMPANY: FORMER CONFORMED NAME: Kinex Pharmaceuticals, Inc. DATE OF NAME CHANGE: 20131223 FORMER COMPANY: FORMER CONFORMED NAME: Kinex Pharmaceuticals LLC DATE OF NAME CHANGE: 20040817 8-K 1 d470846d8k.htm 8-K 8-K
US false 0001300699 0001300699 2023-05-09 2023-05-09

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 9, 2023

 

 

ATHENEX, INC.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-38112   43-1985966

(State or other jurisdiction

of incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

 

1001 Main Street, Suite 600, Buffalo, New York   14203
(Address of principal executive offices)   (Zip Code)

Registrant’s telephone number, including area code: (716) 427-2950

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

  ☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

  ☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

  ☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

  ☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Exchange Act:

 

Title of each class

  

Trading
Symbol(s)

  

Name of each exchange

on which registered

Common Stock, par value $0.001 per share   ATNX   The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

 

 

 

Item 1.03

Bankruptcy or Receivership.

On May 14, 2023 (the “Petition Date”), Athenex, Inc. (the “Company”) together with certain of its subsidiaries (collectively, the “Debtors”) filed voluntary petitions for relief under Chapter 11 of the United States Bankruptcy Code (the “Code”) with the United States Bankruptcy Court for the Southern District of Texas (the “Bankruptcy Court”). On the Petition Date, the Debtors filed a motion with the Bankruptcy Court seeking to jointly administer the Chapter 11 cases under the caption “In re: Athenex, Inc., et al.” (Case No. 23-90295) (the “Chapter 11 Case”).

The Debtors expect to continue to operate their businesses as “debtors-in-possession” under the jurisdiction of the Bankruptcy Court and in accordance with the provisions of the Code and the orders of the Bankruptcy Court. Also on the Petition Date, the Debtors filed with the Bankruptcy Court motions seeking a variety of “first day” customary relief intended to enable the Company to continue its ordinary course operations and to facilitate an orderly wind down of its operations. The Company intends to sell substantially all of its assets during the Chapter 11 Case pursuant to a competitive bidding and auction process. The Company cannot be certain that holders of the Company’s common stock will receive any payment or other distribution for those shares following the Chapter 11 Case.

Also on May 14, 2023, the Company issued a press release in connection with the filing of the Chapter 11 Case. A copy of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and incorporated by reference herein.

 

Item 2.04

Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement.

The filing of the Chapter 11 Case constituted an event of default that accelerated the Company’s obligations under certain agreements relating to direct financial obligations of the Company, including:

 

  •  

the senior secured loan agreement dated as of June 19, 2020, as amended from time to time, with Oaktree Fund Administration, LLC, as administrative agent, and the lenders party thereto (the “Senior Credit Agreement”), with respect to an aggregate outstanding principal amount of approximately $41.875 million, together with accrued interest and all applicable fees and other financial obligations under the Senior Credit Agreement; and

 

  •  

the revenue interest purchase agreement, dated as of June 21, 2022, between the Company and ATNX SPV, LLC, on the one hand, and affiliates of Sagard Healthcare Partners and funds managed by Oaktree Capital Management, L.P., on the other hand.

The filing of the Chapter 11 Case automatically stayed most actions against the Debtors. Subject to certain exceptions under the Code, the filing of the Debtors’ Chapter 11 Case also automatically stayed the continuation of most legal proceedings or the filing of other actions against or on behalf of the Debtors or their properties to recover on, collect or secure a claim arising prior to the Petition Date or to exercise control over properties of the Debtors’ bankruptcy estates, unless and until the Bankruptcy Court modifies or lifts the automatic stay as to any such claim.

 

Item 2.05

Costs Associated with Exit or Disposal Activities.

On May 9, 2023, the Company’s board of directors (“Board”) authorized the termination of approximately 140 employees, or approximately 67% of the Company’s current employees, effective May 12, 2023 and restructured the Company’s operations to maintain a transition team of approximately 68 employees to continue operations in connection with the Chapter 11 Case. The Company recorded a one-time charge of approximately $1.3 million related to the reduction in its workforce, consisting primarily of one-time severance payments upon termination of the employees.

 

Item 3.01

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

On May 16, 2023, the Company received written notice from the Listing Qualifications Department of the Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, as a result of the Chapter 11 Case and in accordance with Nasdaq Listing Rules 5101, 5110(b), and IM-5101-1, the Nasdaq staff determined that the Company’s common stock will be delisted from Nasdaq. The Company does not intend to appeal this determination. Trading of the Company’s common stock will be suspended at the opening of business on May 25, 2023.

Item 5.02

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On May 9, 2023, the Board terminated Salary Deduction and Stock Purchase Agreements between the Company and certain of its directors and executive officers effective immediately.

On May 12, 2023, the Board appointed Joe Annoni to serve as the Company’s Assistant Chief Restructuring Officer in addition to his duties as Chief Financial Officer. Also on May 12, 2023, the Company increased the base salary of its Chief Financial Officer, Joe Annoni, from $288,750 to $360,000 and reduced the base salary of Daniel Lang from $325,000 per year to $162,500 per year. These salary adjustments take effect immediately.

Cautionary Note Regarding the Company’s Common Stock

The Company cautions that trading in the Company’s common stock during the pendency of the Chapter 11 Case is highly speculative and poses substantial risks. Trading prices for the Company’s common stock may bear little or no relationship to the actual recovery, if any, by holders of the Company’s common stock in the Chapter 11 Case. Accordingly, the Company urges extreme caution with respect to existing and future investments in its common stock.

Cautionary Note Regarding Forward-Looking Statements

Except for historical information, information in this Current Report on Form 8-K and the exhibit hereto consists of forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks, uncertainties and assumptions that are difficult to predict. Words such as “expect,” “intend,” “may,” “seek,” and similar expressions, or the use of future tense, identify forward-looking statements, but their absence does not mean that a statement is not forward-looking. Actual results might differ materially from those explicit or implicit in the forward-looking statements. These forward-looking statements are subject to a number of risks, uncertainties and assumptions including: risks inherent in the bankruptcy process, including the Company’s ability to obtain approval from the Bankruptcy Court for motions or other requests made throughout the course of the Chapter 11 Case; the Company’s liquidity and financial position; the effects of the Chapter 11 Case on the Company’s operations; the Company’s ability to continue to operate its business during the pendency of the Chapter 11 Case, and the availability of operating capital during the Chapter 11 Case; the Company’s ability to maintain relationships with partners, suppliers, customers, employees, regulatory authorities and other third parties; the length of time that the Company will operate under Chapter 11 protection; objections to the Company’s restructuring or liquidation process, third-party motions, or other pleadings filed that could protract the Chapter 11 Case; and Bankruptcy Court rulings in the Chapter 11 Case and the outcome of the Chapter 11 Case, in general. You should not rely upon forward-looking statements as predictions of future events. The Company undertakes no obligation to update publicly any forward-looking statements for any reason after the date of this Current Report on Form 8-K to conform these statements to actual results or to changes in its expectations, except as required by law.

 

Item 9.01

Financial Statements and Exhibits.

(d)    Exhibits

 

Exhibit
No.		   

Description

99.1    Press release dated May 14, 2023
104    Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    ATHENEX, INC.
Date: May 22, 2023    

/s/ Joe Annoni

    Name:   Joe Annoni
    Title:   Chief Financial Officer
 EX-99.1 2 d470846dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

 

LOGO

Athenex, Inc. Reaches Agreement With Lenders to Pursue Expedited Sales Process

To Best Facilitate, Company Voluntarily Files Chapter 11 Proceedings

Company Has Sufficient Resources to Support Athenex Pharma Solutions Operations and Fulfill APD Customer Orders During Process

BUFFALO, N.Y., May 14, 2023 – Athenex, Inc., (NASDAQ: ATNX) (“Athenex” or the “Company”), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that, following an ongoing strategic review, it has reached agreement with its lenders to move forward with an expedited sales process of the Company’s assets across its primary businesses: Athenex Pharmaceutical Division (“APD”), Orascovery, and Cell Therapy.

To best facilitate this process, Athenex and certain of its subsidiaries filed voluntary proceedings under Chapter 11 of the U.S. Bankruptcy Code in the U.S. Bankruptcy Court for the Southern District of Texas. This will enable the Company to divest its assets and wind down the Athenex platform in an orderly fashion, while seeking to maximize value for its stakeholders. The Company anticipates concluding the expedited sales process by July 1, 2023, with the Chapter 11 cases continuing thereafter to resolve claims.

Athenex has also reached an agreement with its secured lenders, subject to court approval, for the consensual use of cash collateral, which will enable the Company to, among other things, satisfy certain obligations to its vendors for authorized goods received and services rendered after the filing. Athenex Pharma Solutions (“APS”), which includes the Company’s manufacturing facility in Clarence, New York, is expected to continue its operations for at least the next 90 days, to provide commercial supply of tirbanibulin ointment. In addition, APD is continuing to operate in the ordinary course and fill customer orders with the ample inventory it has on hand.

Dr. Johnson Lau, Chief Executive Officer of Athenex, on behalf of the management team and the Athenex Board of Directors, said, “Throughout our history, we have sought to become a leader in bringing innovative cancer treatments to the market and improving patient health outcomes. Our team was successful in bringing tirbanibulin, through regulatory approvals, to the U.S. market and a number of EU countries, as well as Taiwan. Unfortunately, our oral paclitaxel product candidate received a complete response letter from the U.S. Food and Drug Administration, and this significant regulatory setback, coupled with challenging biotech markets and the difficult economic environment, put tremendous pressure on our ability to continue to fund our businesses.

“Over the past two years, we made considerable progress in refocusing our business around our promising NKT cell therapy platform, monetizing non-core assets to improve our balance sheet and extending our cash runway, paying down $108 million of debt, and undertaking a comprehensive review of strategic alternatives to create value for our stakeholders. While we explored every viable avenue to avoid this outcome, an orderly sales process represents the best path forward at this time.

“Our goal remains to identify purchasers who will continue development of the important drug candidates for which we have established a good foundation, and to bring them to market on behalf of medical practitioners and, most importantly, for patients. We are incredibly thankful to our team for their dedication to Athenex and will look to support our colleagues through this transition period.”

Additional information regarding Athenex’s Chapter 11 filing is available at https://dm.epiq11.com/athenex; by calling the Company’s claims agent, Epiq, at 888-601-3094 (toll-free) or +1 503-433-8501 (international); or by sending an email to Athenex@epiqglobal.com.

Pachulski Stang Ziehl & Jones LLP is acting as Athenex’s legal counsel. MERU is serving as its financial advisor and Cassel Salpeter & Co., LLC as its investment banker.

About Athenex, Inc.

Founded in 2003, Athenex, Inc. is a clinical-stage biopharmaceutical company dedicated to becoming a leader in the discovery, development, and commercialization of next-generation cell therapy products for the treatment of cancer. The Company’s mission is to become a leader in bringing innovative cancer treatments to the market and to improve patient health outcomes. In pursuit of this mission, Athenex leverages years of experience in research and development, clinical trials, regulatory standards, and manufacturing. The Company is focused on its innovative Cell Therapy platform, based on natural killer T (“NKT”) cells. For more information, please visit www.athenex.com.

Forward-Looking Statements

Except for historical information, information in this press release consists of forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks, uncertainties and assumptions that are difficult to predict. Words such as “anticipate,” “could,” “expect,” “may,” “seek,” “will,” and similar expressions, or the use of future tense, identify forward-looking statements, but their absence does not mean that a statement is not forward-looking. Actual results might differ materially from those explicit or implicit in the forward-looking statements. These forward-looking statements are subject to a number of risks, uncertainties and assumptions including: risks inherent in the bankruptcy process, including the Company’s ability to obtain approval from the Bankruptcy Court for motions or other requests made throughout the course of the Chapter 11 proceedings; the Company’s liquidity and financial position; the effects of the Chapter 11 proceedings on the Company’s operations; the Company’s ability to continue to operate its business during the pendency of the Chapter 11 proceedings, and the availability of operating capital during the Chapter 11 proceedings; the Company’s ability to maintain relationships with partners, suppliers, customers, employees, regulatory authorities and other third parties; the length of time that the Company will operate under Chapter 11 protection; objections to the Company’s restructuring or liquidation process, third-party motions, or other pleadings filed that could protract the Chapter 11 proceedings; and Bankruptcy Court rulings in the Chapter 11 proceedings and the outcome of the Chapter 11 proceedings, in general. You should not rely upon forward-looking statements as predictions of future events. The Company undertakes no obligation to update publicly any forward-looking statements for any reason after the date of this press release to conform these statements to actual results or to changes in its expectations, except as required by law.

Investor Contacts

IR@athenex.com

716.427.2952

Media Contacts

Daniel Yunger / Wendi Kopsick

Kekst CNC

AthenexMediaInquiries@kekstcnc.com

EX-101.SCH 3 atnx-20230509.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 4 atnx-20230509_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Entity Address, Country Entity Address, Country Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company EX-101.PRE 5 atnx-20230509_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 g470846g0522233428399.jpg GRAPHIC begin 644 g470846g0522233428399.jpg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end XML 7 R1.htm IDEA: XBRL DOCUMENT v3.23.1
Document and Entity Information
May 09, 2023
Cover [Abstract]  
Entity Address, Country US
Amendment Flag false
Entity Central Index Key 0001300699
Document Type 8-K
Document Period End Date May 09, 2023
Entity Registrant Name ATHENEX, INC.
Entity Incorporation State Country Code DE
Entity File Number 001-38112
Entity Tax Identification Number 43-1985966
Entity Address, Address Line One 1001 Main Street
Entity Address, Address Line Two Suite 600
Entity Address, City or Town Buffalo
Entity Address, State or Province NY
Entity Address, Postal Zip Code 14203
City Area Code (716)
Local Phone Number 427-2950
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, par value $0.001 per share
Trading Symbol ATNX
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 8 d470846d8k_htm.xml IDEA: XBRL DOCUMENT 0001300699 2023-05-09 2023-05-09 US false 0001300699 8-K 2023-05-09 ATHENEX, INC. DE 001-38112 43-1985966 1001 Main Street Suite 600 Buffalo NY 14203 (716) 427-2950 false false false false Common Stock, par value $0.001 per share ATNX NASDAQ false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.1 html 1 24 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.athenex.com//20230509/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports [EFM.6.05.45.cover-page-fact-not-visible] Submission type 8-K has 1 cover page fact(s) in ix:hidden that should be visible or referenced by an -sec-ix-hidden style property: EntityAddressCountry - d470846d8k.htm 7 - d470846d8k.htm 7 d470846d8k.htm atnx-20230509.xsd atnx-20230509_lab.xml atnx-20230509_pre.xml d470846dex991.htm http://xbrl.sec.gov/dei/2022 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "d470846d8k.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2022": 24 }, "contextCount": 1, "dts": { "inline": { "local": [ "d470846d8k.htm" ] }, "labelLink": { "local": [ "atnx-20230509_lab.xml" ] }, "presentationLink": { "local": [ "atnx-20230509_pre.xml" ] }, "schema": { "local": [ "atnx-20230509.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd", "https://xbrl.sec.gov/naics/2022/naics-2022.xsd" ] } }, "elementCount": 25, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 3, "total": 3 }, "keyCustom": 0, "keyStandard": 24, "memberCustom": 0, "memberStandard": 0, "nsprefix": "atnx", "nsuri": "http://www.athenex.com/20230509", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "div", "div", "body", "html" ], "baseRef": "d470846d8k.htm", "contextRef": "duration_2023-05-09_to_2023-05-09", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "menuCat": "Cover", "order": "1", "role": "http://www.athenex.com//20230509/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "div", "div", "body", "html" ], "baseRef": "d470846d8k.htm", "contextRef": "duration_2023-05-09_to_2023-05-09", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.athenex.com//20230509/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.athenex.com//20230509/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.athenex.com//20230509/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.athenex.com//20230509/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.athenex.com//20230509/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.athenex.com//20230509/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.athenex.com//20230509/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country", "terseLabel": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.athenex.com//20230509/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.athenex.com//20230509/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.athenex.com//20230509/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.athenex.com//20230509/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.athenex.com//20230509/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.athenex.com//20230509/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.athenex.com//20230509/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.athenex.com//20230509/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.athenex.com//20230509/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.athenex.com//20230509/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.athenex.com//20230509/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.athenex.com//20230509/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security 12b Title", "terseLabel": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.athenex.com//20230509/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.athenex.com//20230509/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.athenex.com//20230509/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.athenex.com//20230509/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.athenex.com//20230509/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 16 0001193125-23-150484-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-23-150484-xbrl.zip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end